Scarica l'app Stockscreener
321.71
0.16%
-0.52
Dopo l'orario di chiusura:
321.71
Precedente Chiudi:
$322.23
Aprire:
$321.88
Volume 24 ore:
345.79K
Relative Volume:
0.56
Capitalizzazione di mercato:
$12.65B
Reddito:
$1.40B
Utile/perdita netta:
$177.69M
Rapporto P/E:
71.12
EPS:
4.5234
Flusso di cassa netto:
$174.93M
1 W Prestazione:
-0.91%
1M Prestazione:
-2.44%
6M Prestazione:
+15.03%
1 anno Prestazione:
+8.20%
Intervallo 1D:
$321.38
$323.07
Intervallo di 1 settimana:
$321.38
$326.43
Portata 52W:
$221.26
$362.41
Penumbra Inc Stock (PEN) Company Profile
Nome
Penumbra Inc
Settore
Industria
Telefono
(510) 995-2486
Indirizzo
ONE PENUMBRA PLACE, ALAMEDA, CA
Compare PEN vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
321.71 | 12.67B | 1.40B | 177.69M | 174.93M | 4.5234 |
ABT
Abbott Laboratories
|
82.56 | 146.87B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
282.58 | 109.33B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
74.54 | 97.77B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
53.37 | 80.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
77.17 | 46.04B | 6.30B | 1.07B | 1.09B | 1.8406 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-18 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-12-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-11-18 | Iniziato | Wells Fargo | Underweight |
| 2025-10-08 | Aggiornamento | Needham | Hold → Buy |
| 2025-09-02 | Iniziato | Evercore ISI | Outperform |
| 2025-03-14 | Iniziato | BofA Securities | Buy |
| 2025-01-21 | Iniziato | UBS | Buy |
| 2024-12-17 | Iniziato | Oppenheimer | Outperform |
| 2024-12-11 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-09-18 | Iniziato | Stifel | Buy |
| 2024-09-03 | Iniziato | Leerink Partners | Outperform |
| 2024-07-31 | Downgrade | Citigroup | Buy → Neutral |
| 2024-07-31 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-02-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-09-06 | Iniziato | Morgan Stanley | Equal-Weight |
| 2023-07-19 | Iniziato | Robert W. Baird | Outperform |
| 2023-03-29 | Downgrade | Needham | Buy → Hold |
| 2023-01-30 | Iniziato | Piper Sandler | Overweight |
| 2022-11-04 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-10-05 | Downgrade | Citigroup | Buy → Neutral |
| 2022-09-09 | Aggiornamento | Needham | Hold → Buy |
| 2022-07-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-04-19 | Iniziato | Deutsche Bank | Buy |
| 2022-03-08 | Iniziato | Needham | Hold |
| 2021-09-16 | Iniziato | Truist | Buy |
| 2021-06-04 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-12-16 | Downgrade | BTIG Research | Buy → Neutral |
| 2020-10-07 | Ripresa | Canaccord Genuity | Buy |
| 2020-09-29 | Iniziato | BTIG Research | Buy |
| 2020-09-08 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-06-13 | Reiterato | BofA/Merrill | Buy |
| 2019-05-30 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-05-21 | Iniziato | William Blair | Outperform |
| 2018-10-29 | Ripresa | BofA/Merrill | Buy |
| 2018-10-08 | Iniziato | RBC Capital Mkts | Outperform |
| 2018-02-21 | Iniziato | William Blair | Outperform |
| 2018-01-02 | Downgrade | JP Morgan | Overweight → Neutral |
| 2015-11-30 | Reiterato | Canaccord Genuity | Buy |
| 2015-10-13 | Iniziato | Wells Fargo | Outperform |
Mostra tutto
Penumbra Inc Borsa (PEN) Ultime notizie
Penumbra, Inc. Reports Third Quarter 2025 Financial Results - Quantisnow
Penumbra Shareholders Approve Merger with Boston Scientific - The Globe and Mail
Penumbra revenue up 15.6% to USD 374.8M in Q1 2026 - Medical Buyer
PEN Maintained by Citigroup -- Price Target Lowered to $350 - GuruFocus
Penumbra (PEN) Margin Expansion To 11.8% Tests Bulls High P E Narrative - Sahm
Citi Maintains Penumbra(PEN.US) With Hold Rating, Cuts Target Price to $350 - Moomoo
Penumbra Is Maintained at Outperform by Evercore ISI Group - Moomoo
Liquidity Mapping Around (PEN) Price Events - Stock Traders Daily
PEN Maintained by Evercore ISI Group -- Price Target Lowered to $335 - GuruFocus
Penumbra Is a 'Strong' Strategic Fit for Boston Scientific, RBC Says - Moomoo
Penumbra shareholders approve merger with Boston Scientific By Investing.com - Investing.com Australia
Penumbra, Inc. Q1 2026 Financial Results: Earnings, Comprehensive Income, and Stockholders’ Equity Highlights - Minichart
Penumbra IncStockholders approve merger with Boston ScientificSEC filing - marketscreener.com
Penumbra shareholders approve merger with Boston Scientific - Investing.com
Penumbra (NYSE: PEN) shareholders approve Merger Proposal; closing conditions remain - Stock Titan
Penumbra (NYSE: PEN) investors back merger, await antitrust approvals - Stock Titan
Evercore Maintains Penumbra(PEN.US) With Buy Rating, Cuts Target Price to $335 - Moomoo
Penumbra: Q1 Earnings Snapshot - theheraldreview.com
Assessing Penumbra (PEN) Valuation As Growth Expectations Meet A Premium P/E Multiple - Yahoo Finance
PEN Stock Price, Quote & Chart | PENUMBRA INC (NYSE:PEN) - ChartMill
Penumbra Shareholder Notice - TMX Newsfile
MSN Money - MSN
Penumbra (PEN) Misses Q1 Earnings Estimates - Yahoo Finance
[10-Q] Penumbra Inc Quarterly Earnings Report - Stock Titan
Earnings Flash (PEN) Penumbra, Inc. Reports Q1 Revenue $374.8M, vs. FactSet Est of $371.3M - marketscreener.com
Penumbra (NYSE: PEN) posts $374.8M Q1 2026 revenue as Boston Scientific deal looms - Stock Titan
Penumbra posts $32.6M profit as Boston Scientific deal halts outlook - Stock Titan
Penumbra, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
PEN Technical Analysis | Trend, Signals & Chart Patterns | PENUMBRA INC (NYSE:PEN) - ChartMill
Penumbra earnings in focus as Boston Scientific deal looms By Investing.com - Investing.com South Africa
Penumbra earnings in focus as Boston Scientific deal looms - Investing.com
Penumbra, Inc. (PEN) Stock Analysis: A 12.44% Potential Upside in the Thriving Medical Devices Sector - DirectorsTalk Interviews
Vanguard Group Inc. Cuts Stock Position in Penumbra, Inc. $PEN - MarketBeat
Inside Boston Scientific's $15 billion offer for Alameda's largest employer - The Business Journals
Penumbra, Inc. (NYSE:PEN) Sees Large Drop in Short Interest - MarketBeat
Vanguard Capital Management (NYSE: PEN) holds 1.99M shares, 5.07% stake - Stock Titan
[ARS] Penumbra Inc SEC Filing - Stock Titan
Penumbra (PEN) down 1.6% since last earnings report: Can it rebound? - MSN
Penumbra (NYSE: PEN) outlines 2026 meeting and $14.5B Boston Scientific sale - Stock Titan
Teacher Retirement System of Texas Reduces Stake in Penumbra, Inc. $PEN - MarketBeat
3 Reasons Why Penumbra (PEN) Is a Great Growth Stock - Yahoo Finance
Investor Outlook: Penumbra, Inc. (PEN) Eyes 10.88% Upside With Strong Revenue Growth - DirectorsTalk Interviews
A Look At Penumbra (PEN) Valuation After Positive STORM PE Trial Outcomes - Sahm
Why (PEN) Price Action Is Critical for Tactical Trading - Stock Traders Daily
How STORM-PE Thrombectomy Results and Lightning Flash Data Will Impact Penumbra (PEN) Investors - simplywall.st
Penumbra Inc Azioni (PEN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):